Atea Pharmaceuticals, Inc. (AVIR) Form 8-K — May 12, 2026
Atea Pharmaceuticals reported its first quarter 2026 financial results, ending the period with $256.0 million in cash, cash equivalents, and marketable securities. The company recorded a net loss of $45.4 million, or $0.57 per share, driven by a $41.1 million investment in research and development expenses related to its Phase 3 HCV program and HEV preclinical studies. Operationally, Atea confirmed that topline data from the C-BEYOND Phase 3 trial is expected in mid-2026, with C-FORWARD results anticipated around year-end. The company also announced it anticipates initiating a Phase 1 clinical trial for AT-587, a potential first-in-class therapy for Hepatitis E virus, in mid-2026.
Key figures
- Total Assets
- 267076000
- Cash Position
- 256006000
- Ga Expenses
- 6874000
- Rd Expenses
- 41134000
- Working Capital
- 229830000
Price after filing
Close on the filing date to close N calendar days later (from $5.50). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.